Somerville's bluebird bio nets 3rd gene therapy approval since company split

Somerville's bluebird bio Inc. has won its third U.S. drug approval since splitting into two companies.

On Friday, the Food and Drug Administration approved lovo-cel, a gene therapy for sickle-cell disease. The drug will be marketed under the name Lyfgenia.

WATCH ANYTIME FOR FREE

Stream NBC10 Boston news for free, 24/7, wherever you are.

More on this story from Boston Business Journal